ABSTRACT
We developed a new optical method to determine the rate of reverse intersystem crossing (krISC) in thermally activated delayed fluorescent (TADF) organic chromophores using time-resolved transient absorption spectroscopy. We successfully correlated the krISC of the TADF-chromophores with device performance. Specifically, we focused on the external quantum efficiency (ηEQE) and the stability of the device at high brightness levels. It is believed that by obtaining a large krISC one may reduce the possibility of triplet-triplet annihilation (TTA) and increase the long-term stability of organic light emitting diodes (OLEDs) devices at high brightness levels (ηEQE roll-off). In this contribution, we investigate the photophysical mechanism in a series of TADF-chromophores based on carbazole or acridine derivatives as donor moieties, and triazine or benzonitrile derivatives as the acceptor moieties. We found a relationship between large krISC values and high ηEQE values at low operating voltages for the TADF-chromophores investigated. In addition, those chromophores with a larger krISC illustrated a smaller ηEQE roll-off (higher stability) at high operating voltages. These features are beneficial for superior OLEDs performing devices. Contrarily, we found that if a chromophore has a krISC ≤ 105s-1 its ηEQE is ≤5%. Such a small krISC suggests that there is no TADF effect operating in these organic systems and the molecule is not efficient in harvesting triplet excitons. Emission lifetime-based methodologies for determining the krISC were included for comparison but failed to predict the devices performance of the investigated TADF-chromophores to the same extent of our proposed methodology.
ABSTRACT
The purposes of this study were to compare the perceived and actual 10-year risk for cardiovascular disease (CVD) and to evaluate the influence of cardiovascular risk factors on perceived CVD risk in patients with rheumatoid arthritis (RA) in Korea. Additionally, the attainment of CVD prevention guideline goals by 3 levels of CVD risk (low, moderate, and high) was presented.For this cross-sectional study, data were collected from 208 patients with RA. Actual CVD risk was estimated with the Systematic Coronary Risk Evaluation (SCORE), and goal attainment was assessed based on the European League Against Rheumatism guidelines. Actual CVD risk and perceived risk were compared with cross-tabulation. Chi-square tests were used to evaluate differences in cardiovascular risk factors by perceived risk. Levels of goal attainment were presented in percentages.Among patients with RA, 13.9% were identified as being at high risk for CVD, whereas 39.9% were at moderate risk, and 46.2% were at low risk. The majority of those at high risk (96.6%) underestimated their risk for CVD. The use of antihypertensive or lipid-lowering medications and having a parental history of CVD significantly increased the likelihood that subjects with RA would perceive themselves as being at high risk for CVD. Diabetes, smoking, physical inactivity, and obesity did not affect perceived risk. A substantial proportion of the subjects with RA did not meet the prevention guideline goals.Patients with RA who are at increased risk of developing CVD must be managed as soon as possible to attain the guideline goals and, accordingly, lower their risk of future CVD.
